Preeclampsia (PE) is a major cause of maternal and perinatal mortality, especially in developing countries. Its etiology involves multiple factors, but no specific cause has been identified. Evidence suggests that clinical manifestations are caused by endothelial dysfunction. Nitric oxide (NO), which is synthesized from L-arginine in endothelial cells by the endothelial nitric oxide synthase (eNOS), provides a tonic dilator tone and regulates the adhesion of white blood cells and platelet aggregation. Alterations in the L-arginine-NO pathway have been associated with the development of PE. Various studies, reporting decreased, elevated or unchanged levels of nitrite (NO 2 ) and nitrate (NO 3 ), two end products of NO metabolism, have been published. Our group contributed to those contradictory reports describing cases of PE with both elevated and decreased levels of NO 2 and NO 3 . Apparently, diminished levels of NO could be related to deficiencies in the ingestion of dietary calcium associated to low levels of plasma ionic calcium, which is crucial to the eNOS' activity. Also, low levels of NO could be associated with the presence of eNOS polymorphisms or the presence of increased levels of ADMA, the endogenous inhibitor of NO. High levels of NO associated to low levels of cGMP suggest a decreased bioactivity of NO, which is probably related to an increased degradation of NO caused by a high production of superoxide in states of infection and inflammation. The present article analyses and reviews the reported paradoxical roles of the L-arginine-NO pathway in PE and gives a possible explanation for these results.
Introduction
Hypertensive pregnancy disorders are the main cause of maternal and perinatal morbidity and mortality. Preeclampsia (PE) is the most important among these pathologies [WHO, 2004; Walker, 2000] Preeclampsia, defined as the onset of hypertension and proteinuria after 20 weeks of gestation in previously normotensive nonproteinuric pregnant women [Walker, 2000] , is a multiorgan disease, affecting the liver, kidneys, brain, and blood clotting system. Despite its importance, the etiology of PE is not well defined and multiple risk factors have been identified Lopez-Jaramillo, 2000 ]. The impact of each of them varies in different populations, with considerable differences between developed and developing countries . In Latin America, the high frequency of risk factors, such as inappropriate nutrition, young maternal age, and inadequate prenatal care programs, is reflected in the high incidence of PE [WHO, 2004 [WHO, , 1987 and elevated maternal Correspondence to:
(eNOS) is a NADPH and Ca 2+ dependent enzyme [Moncada et al. 1991] . Moreover, we have demonstrated the crucial role of extracellular calcium concentrations in the production of endothelial NO and in the control of vascular tone . NO acts as a potent vasodilator via the activation of cGMP [Sladek et al. 1997] (Figure 1 ). eNOS is expressed in human placental syncytiotrophoblasts and extravillous trophoblasts [Sladek et al. 1997] . NO is inactivated when reacting with superoxide (O − 2 ) to form peroxynitrite (ONOO − ) a potent oxidant responsible for the lipid peroxidation and the nitration of tyrosine. An increased production of O − 2 during pregnancy has been reported, especially in case of infection and/or inflammation. Moreover, O − 2 is produced by eNOS when there is a deficiency of tetrahydrobiopterin (BH 4 ) [Ronson et al. 1999; Moncada et al. 1991] .
The aim of the present review was to evaluate the role of the L-arginine-NO pathway in normal pregnancy, and to analyze the conflicting results reported in the literature about the role of NO in PE. We searched PubMed for articles published between 1990 and 2005. The keywords used were 'Preeclampsia,' 'nitric oxide,' 'nitrites/ nitrates,' 'cyclic guanosine monophosphate,' and 'L-arginine. ' We also searched the bibliographies of the articles retrieved for further relevant references. Reports, letters to the editor and papers not specifically focused on this topic were excluded. Because of the large number of articles identified, the decision on which to include was based on personal judgment.
Hemodynamic changes in normal pregnancy
Normal pregnancy is characterized by profound anatomical, physiological, and biochemical changes to support growth and development of the fetus [Heilmann, 1987; Taylor and Lind, 1979; Chesley, 1972; Lund and Donovan, 1967] . The hemodynamic changes observed during pregnancy are: increased blood volume, heart rate, cardiac output, and a decreased peripheral vascular resistance [Moutquin et al. 1985; Metcalfe and Ueland, 1974; Lees et al. 1967 ]. This decrease in resistance is achieved by both peripheral vasodilatation and reduction in blood viscosity [Heilmann, 1987] .
In normal pregnancy, plasma volume increases to about 40% above pre-pregnancy levels at 30-week gestation [Chesley, 1972; Lund and Donovan, 1967] . Furthermore, during gestation red cell mass increases linearly to reach at term, a level 25% higher than before pregnancy Review [Taylor and Lind, 1979; Chesley, 1972; Lund and Donovan, 1967] , besides cardiac output rises from 30 to 40% compared with nonpregnant resting stage [Lees et al. 1967] . The increase in cardiac output occurs as early as the twelveth week, probably as a result of afterload due to peripheral vasodilation [Metcalfe and Ueland, 1974] . Despite these increases in cardiac output and plasma volume, blood pressure falls during normal pregnancy [Moutquin et al. 1985] . The reasons for the fall in peripheral vascular resistance have not been completely established but have been associated with an increased production of prostacyclin and NO [Lopez-Jaramillo et al. 1995; Felix et al. 1991 ].
An important body of evidence suggests that an increased endothelial NO production is implicated in normal pregnant vasodilation [Williams et al. 1997] . Table 1 summarizes some of the studies demonstrating that the production of NO, evaluated by the plasma and serum levels of NO 2 and NO 3 [Schiessl et al. 2006; Teran et al. 2006; D'Anna et al. 2004; Diejomaoh et al. 2004; Makkonen et al. 2002; Vural, 2002; Yoneyama et al. 2002; Nishikawa et al. 2000; Shaamash et al. 2000; Conrad et al. 1999; Egerman et al. 1999; Hata et al. 1999; Lopez-Jaramillo et al. 1992] , the bioactivity of NO evaluated by cGMP levels in biological fluids or in platelets [Baksu et al. 2005; Teran et al. 2004; Shaamash et al. 2000; Conrad et al. 1999; Lopez-Jaramillo et al. 1996; Schneider et al. 1996; ] and, the biological effect of NO in the vasculature, evaluated by flowmediated vasodilation (FMD) [Saarelainen et al. 2006; Sierra-Laguado et al. 2006; Yamamoto et al. 2005; Savvidou et al. 2000; Dorup et al. 1999; Cockell and Poston, 1997] , are all increased in normal pregnant women, in relation with normotensive nonpregnant women. Thus, nowadays, there is no doubt that an increased production of NO in the vascular endothelium and a normal bioactivity of NO are the critical mechanisms that explain the hemodynamical adaptations during pregnancy.
Alterations of the L-arginine-nitric oxide pathway in PE
The most characteristic alteration of PE is a generalized peripheral vasoconstriction [Walker, 2000] . It has been proposed that an altered production of endothelial NO could be the reason for vasoconstriction in PE [Schiessl et al. 2006; Baksu et al. 2005; Xiang et al. 2005; Yamamoto et al. 2005; Aydin et al. 2004; D'Anna et al. 2004; Diejomaoh et al. 2004; Teran et al. 2004 Teran et al. , 2006 Celik et al. 2003a,b; Var et al. 2003; Makkonen et al. 2002; Vural, 2002; Yoneyama et al. 2002; Nishikawa et al. 2000; Shaamash et al. 2000; Conrad et al. 1999; Egerman et al. 1999; Hata et al. 1999; Dorup et al. 1999; Mutlu-Turkoglu et al. 1999; Norris et al. 1999; Ranta et al. 1999; Cockell and Poston, 1997; Begum et al. 1996; Davidge et al. 1996; Lopez-Jaramillo et al. 1996; Schneider et al. 1996; Silver et al. 1996; Seligman et al. 1994; Lopez-Jaramillo et al. 1992 ].
In animal models, the inhibition of NO production leads to findings similar to those reported in human PE, including hypertension, proteinuria, and fetal growth restriction [Deng et al. 1996 ].
Several approaches have been used to study the role of NO in PE. NO is a molecule, which is quickly removed by its rapid diffusion through tissues into red blood cells. This limits the biological half-life of NO in vivo to less than a second. The existing analytical methods have several limitations in the measurement of NO [Yao et al. 2004] . The most used method to study NO production has been the quantification of NO 2 /NO 3 levels in plasma and serum [Seligman et al. 1994 ]. The results from several reports of the NO 2 /NO 3 levels in preeclamptic women are summarized in Table 2 . However, most of the reports involved a small sample number, and used different methods to quantify NO 2 /NO 3 .
These studies showed paradoxical results with elevated, decreased, or unchanged NO 2 /NO 3 levels in preeclamptic women, compared with controls. These inconsistent results were also reported by our group in patients from the same population [Lopez-Jaramillo et al. 1998 , 1992 . The initial confusion caused by these results was later clarified by reports showing that independent of NO 2 /NO 3 levels, the concentration of cGMP, determined in plasma, urine, or platelets, was always consistently lower in women with PE (Table 3 ) [Baksu et al. 2005; Teran et al. 2004; Lopez-Jaramillo et al. 1996; Schneider et al. 1996; ] . These results suggested that in some patients with PE, there is a decreased production of NO expressed by low NO 2 /NO 3 levels and cGMP, but in other cases there is a normal or increased production of NO, determined by normal or high NO 2 /NO 3 levels and a decreased bioactivity of NO, expressed by the low levels of cGMP . Moreover, in all the studies [Yamamoto et al. 2005; Takata et al. 2002; Yoshida et al. 2000 ; Table 1 . Levels of metabolites of nitric oxide, cGMP, and FMD in nonpregnant women (NP) and normotensive pregnant women (NTP). Review Table 2 . Levels of NO metabolites in biological fluids of preeclamptic women compared to women with normal pregnancy.
Similar levels
Author/Year Method n
Davidge et al. [1996] Spectrophotometric -Griess reaction 13 Silver et al. [1996] Chemiluminescence 21 Hata et al. [1999] Fluorometric assay 13 Conrad et al. [1999] Griess reaction 15 Egerman et al. [1999] Spectrophotometric 12 Yanik et al. [2001] Spectrophotometer 38 Begum et al. [1996] Griess reaction 12 Mutlu-Türkoglu et al. [1999] Griess reaction 20 Spectrophotometric 21 Griess reaction 20 Var et al. [2003] Griess reaction 19 Aydinl et al. [2004] Colorimetric assay 34 Xiang et al. [2005] Nitrate reductase method 11 Teran et al. [2006] Chemioluminiscence 30
Increased levels
Author/Year Method n Lopez-Jaramillo [1998] Spectrophotometric 10 Ranta et al. [1999] Griess reaction 20 Norris et al. [1999] Griess reaction 16 Nishikawa et al. [2000] Spectrophotometric 17 Shaamash et al. [2000] Griess reaction 31 Makkonen et al. [2002] Colorimetric assay 20 Yoneyama et al. [2002] Griess reaction 25 Vural [2002] The Grisham's method 19 D'Anna et al. [2004] Chemiluminescence detection 30 Paşaoglu et al. [2004] Spectrophotometric 40 n = Number of patients. Cockell and Poston, 1997 ] that reported FMD in women with PE, there was a decreased vasodilating response to hyperemia (Table 3) .
All these results reveal that PE is characterized by a decreased bioavailability of NO, which explains the peripheral vasoconstriction, the endothelial dysfunction, and the clinical manifestations of this disease. Furthermore, these results support the proposal of multicausality of the disease with different mechanisms conducting alterations in the activity of NO Lopez-Jaramillo, 2000 ].
In the case of PE with low production of NO (low NO 2 /NO 3 levels) some alterations in the L-arginine-NO pathway have been described ( Figure 2 ):
1. Deficiency in the substrate L-arginine or in its transport [McCord et al. 2006; Neri et al. 2000 ]. 2. Deficiency in the cofactors needed for the normal activity of eNOS, such as ionic calcium [Herrera et al. 2006; Steinert et al. 2002; Lopez-Jaramillo et al. 2001 ] and BH 4 [Var et al. 2003; Toth, 2002] . 3. Accumulation of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of eNOS [Slaghekke et al. 2006 ]. 4. Presence of polymorphic alterations of the eNOS that results in a lower enzymatic activity ].
In the case of PE with normal or high production of NO and normal or increased NO 2 /NO 3 levels but with lower bioactivity of NO, an increased degradation of NO has been proposed. Due to the high reactivity of NO with O − 2 to form peroxinitrite, increased oxidative stress in PE has been reported as the cause of the rapid degradation of NO [Sharma et al. 2006; Myatt and Cui, 2004; Lowe, 2000; Sagol et al. 1999] . Table 4 summarizes the results of several studies using different methods to evaluate the state of oxidative stress in PE. It is clear that, regardless of the method used to quantify oxygen reactive species, most of the studies found an increased superoxide production in pregnant women with PE [Biri et al. 2007; Chamy et al. 2006; Sharma et al. 2006; Myatt and Cui, 2004; Pasaoglu et al. 2004; Serdar et al. 2002; Diedrich et al. 2001; Yanik et al. 2001; Kharb, 2000; Lowe, 2000; Sagol et al. 1999; Madazli et al. 1999] . Below are some of the causes described to explain the reduced bioavailability of NO and the increased state of oxidative stress in PE. Xia et al. 2003 ]. 2. Early abnormal placentation with placental ischemia and hypoxia [Gilbert et al. 2007 ]. 3. Alterations in the metabolism of carbohydrates and lipids associated to insulin resistance, overweight, and obesity [Joffe et al. 1998 ]. 4. Subclinical infections in the vagina, urinary tract system, and periodontal disease [Herrera et al. 2001 [Herrera et al. , 2007 Trogstad et al. 2001; Hill et al. 1986 ].
Presence of antibodies anti receptors AT1 of angiotensin II [Dechend
A defective placentation has been proposed as the primary cause of preeclampsia [Gilbert et al. 2007 ]. An inadequate trophoblastic invasion of uterine spiral arteries results in placental ischaemia, oxidative stress, inflammation, and alteration of maternal endothelial cell function [Sankaraligam et al. 2006 ]. It has been suggested that a reduced formation of NO could be responsible for the abnormal placental perfusion in PE [Lowe et al. 2000 ]. However, there is accumulating evidence that supports that preeclamptic placenta has a normal capacity to synthesize NO [Baylis et al. 1998 ]. Moreover, as Review we previously mentioned, the concentration of cGMP in placental circulation is lower than normal [Kovasc et al. 1994 ], suggesting that PE is a condition of normal placental production of NO, but with a reduced activity of this substance. One mechanism, by which NO bioavailability is reduced in PE, could be the increased production of oxygen free radicals, which scavenge this potent vasodilator [Sankaraligam et al. 2006 ]. Another pathway that might result in reduced NO bioavailability involves arginase, an enzyme that catalyses the conversion of L-arginine to L-ornithine and urea ]. There are two isoforms of arginase (arginase I and II) that are located in the cytosol and mitochondria, respectively. Noris et al. [2004] found that arginase II m RNA expression was more than 4-fold higher in villous tissue of preeclamptic than in normal pregnant women. In addition, levels of arginase II mRNA in villous tissue correlated inversely with fetal L-arginine concentration, suggesting excess consumption of the substrate. Since L-arginine is also a substrate for NOS, arginase reciprocally regulates NOS [Berkowitz et al. 2003 ]. Higher than normal expression of arginase II causes that less L-arginine be available for eNOS in trophoblast cells than in the villous endothelium. A decrease in the L-arginine concentrations could result in uncoupling of eNOS, thus increasing the generation of O − 2 [Kuzkaya et al. 2003 ]. This might result in increased scavenging of NO by superoxide to generate peroxynitrite [Xia et al. 1996 ]. Markers of oxidative stress are increased in placenta of women with PE, and nitrotyrosine staining, a marker of peroxynitrite, has been found in the preeclamptic placenta [Myatt et al. 1996; Many et al. 2000 ]. The peroxynitrite is an anion that inhibits mitochondrial electron transport, oxidizes proteins, initiates lipid peroxidation, nitrates aromatic amino acids, and decreases prostacyclin synthase expression, producing peripheral vasoconstriction and increasing maternal blood pressure [Radi et al. 1991] . Peroxynitrite also activates pro-inflammatory transcription factors such as NF-κB, which controls expression of adhesion molecules and other inflammatory factors [Li and Karin, 1999] . Thus peroxynitrite contributes to the establishment of the generalized intravascular inflammatory reaction that produces endothelial dysfunction early in pregnancy and predisposes women to a higher risk of developing PE [Sankaraligam et al. 2000 ].
The upregulation of arginase II in PE, provides a potential rational for L-arginine supplementation. A preclinical study performed in rats, showed that L-arginine attenuates the hypertension produced in response to a chronic reduction in uterine perfusion pressure in the pregnant rat, suggesting that L-arginine supplementation may be beneficial in attenuating the hypertension in PE [Alexander et al. 2004] . In humans, administration of L-arginine improves uterine-placental circulation [Neri et al. 1996] , lowers maternal blood pressure [Facchinetti et al. 1999] , and reduces platelet aggregation [Neri et al. 1998 ]. However, few studies have evaluated the effects of L-arginine supplementation on clinical outcomes of women with PE. Staff et al. [2004] evaluated the effects of oral administration of 12 g of L-arginine or placebo on preeclamptic women with gestational length ranging from 28 to 36 weeks. They found no significant effects on diastolic blood pressure values, time of delivery, or mean birth weight between the groups. However, this study was limited by the small sample size (15 subjects in each group) and the short-term treatment (two days). Recently, Facchineti et al. [Facchinetti et al. 2007 ] in a study with a larger sample size demonstrated that the daily intravenous administration of L-arginine (20 g/500 ml), for five days followed by 4 g/day orally administered for two weeks, prolonged pregnancy and reduced blood pressure in women with gestational hypertension in comparison with placebo. Despite these promising results, the effectiveness of L-arginine in preventing the development of PE remains to be determined.
Because oxidative stress has been proposed as a key factor involved in the development of endothelial dysfunction and PE, supplementation with antioxidants, like vitamin C and E, during pregnancy has also been proposed as a possible strategy to prevent or delay the onset of PE. Recently, a systematic review performed by Rumbold et al. [2007] involving seven trials with 6082 women, found that supplementing women with any antioxidant during pregnancy compared with control or placebo was associated with a reduced risk of developing preeclampsia (RR 0.61; 95% CI 0.50-0.75) or having a small-for-gestational-age infant (RR 0.64; 95% CI 0.47-0.87). However, the reviewers mention that these results should be interpreted with caution, and results of larger studies are needed before antioxidants can be recommended for clinical practice.
In addition to an increased oxidative stress, it has been suggested that placenta-derived circulating factors may induce endothelial dysfunction leading to preeclampsia [Maynard et al. 2003 ]. It has been demonstrated that high levels of circulating sFlt1 (soluble fms-like tyrosine kinase) of placental origin, bind to and neutralize the proangiogenic actions of vascular endothelial growth factor (VEGF) and placental growth factor (PIGF). Thus, by preventing the binding of VEFG to Flt1 receptor in cytotrophoblast cells, the excessive production of sFlt1 in placental trophoblast could be responsible for the defective cytotrophoblast differentiation and abnormal placentation of PE [Noris et al. 2005] . High concentrations of sFlt1 along with decreased free VEGF are observed before the onset of clinical symptoms in women with PE [Levine et al. 2004 ]. VEGF also induces endothelial cell production of vasodilatory NO and prostacyclin [Brockelsby et al. 1999] , and may be important in the regulation of vascular tone. It has been suggested that the induction of hypertension by placentaderived sFlt1could be related with the impairment of VEGF-dependent activation of eNOS [Maynard et al. 2003 ]. Recently, it has been found that Endoglina (sEng) or CD105, a cellsurface coreceptor for transforming growth factor (TGF)-β1 and TGF-β3 isoforms, is also elevated in the sera of preeclamptic women. The concentration of this molecule correlates with the disease severity and diminishes after delivery [Venkatesha et al. 2006 ]. sEng impairs binding of TGF-b1 to its receptors and downstream signaling including effects on activation of eNOS and vasodilation, suggesting that sEng leads to dysregulated TGFb signaling in the vasculature, contributing to the endothelial dysfunction characteristic of PE [Venkatesha et al. 2006 ].
Besides the placental factors already explained, there are environmental factors such as insulin resistance and subclinical infections that could also contribute to an increased inflammatory response early in pregnancy, and consequently to the development of endothelial dysfunction and PE. Recently, in two nested case-control studies that involved an important sample of women with PE we reported increased levels of C-reactive protein (CRP), leukocytes count and insulin resistance using the homeostatic model assessment (HOMA); risk factors that precede the development of the clinical manifestations of PE. These alterations were evident as early as in the first trimester of gestation. Moreover, both, high CRP and increased HOMA were associated with a decreased FMD; which suggests that inflammation associated to infection and/or insulin resistance might also be an important cause of the endothelial dysfunction that precedes the development of PE.
Implications in the management of PE
Since huge differences in the PE incidence and mortality are observed between developed and developing countries, the understanding of the different mechanisms that result in an alteration in the L-arginine-NO pathway and endothelial dysfunction is highly important because of its implications in the preventive and therapeutical approaches. For instance, the maternal mortality by PE in UK is about 10/100,000 deliveries and in Colombia is about 176/100,000 deliveries [Lopez-Jaramillo, 2000; WHO International Collaborative Study of Hypertensive Disorders of Pregnancy, 1998 ]. These enormous differences are probably related with the quality of prenatal care, and with the demonstration that in developing countries the nutritional deficiencies and the subclinical chronic infections in pregnant women have a higher prevalence than in developed countries . This situation has been already solved in developed countries where the major risk factors for the PE are genetic and immunological alterations . In support of this proposal, we have demonstrated that ADMA, in our population, has no responsibility in the development of PE [Maas et al. 2004; Lopez-Jaramillo et al. 1996 ]. However, in developed countries, it is an important factor that inhibits the endothelial production of NO [Savvidou et al. 2003; Ellis et al. 2001; Holden et al. 1998; Fickling et al. 1993 ]. This contradictory situation may be related with the fact that the high incidence of infection dilutes the role of ADMA in our population . Preventive interventions to decrease the risk of PE, such as supplementation with calcium [Lopez-Jaramillo, 1996; Lopez-Jaramillo et al. 1997 , 1995 , 1989 , conjugated linoleic acid [Herrera et al. 2005] , early diagnosis, and treatment of infections [Herrera et al. 2001 ], seem to be more determining in clinical trials conducted in developing countries. It is possible that by improving the prenatal care system in undeveloped countries, the prevalence of PE comes to be similar to that observed in developed countries. Therefore, to demonstrate this proposal, an Review international collaborative study comparing the similarities and differences in the incidence of the risk factors for PE between developed and undeveloped countries is necessary. Moreover, such a study will provide further insights about the role of the L-arginine-NO pathway in the etiology of PE.
Conclusions
During pregnancy the adaptative hemodynamic changes are mediated by a higher production of NO and bioactivity of the L-arginine-NO pathway. To guarantee the correct production of NO, different factors such as nutrition, infections, genetic alteration, metabolism, placentation, and maybe ethnical aspects must be considered. An alteration in the NO production or its activity is associated with the development of PE. Both the understanding of the etiology of PE and the role played by the differences in the environmental factors between developed and developing countries, should be a research priority. D'Anna, R., Baviera, G., Corrado, F., Crisafulli, A., Ientile, R., Buemi, M. et al. (2004) Neurokinin B and nitric oxide plasma levels in pre-eclampsia and isolated intrauterine growth restriction. BJOG 111: 1046-1050.
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